Isoprenalina Phagecon

Isoprenaline Hydrochloride, the active ingredient in Isoprenalina Phagecon, is a beta‑adrenergic agonist presented as a sterile solution for intravenous use. It is employed to increase heart rate and contractility in patients with symptomatic bradycardia or heart block, and may be used off‑label as a bronchodilator in asthma.

GNH USA supplies Isoprenalina Phagecon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Isoprenaline acts on the cardiovascular and respiratory systems to correct rhythm disturbances and improve airway tone.

- Symptomatic bradycardia: raises heart rate to relieve dizziness and fatigue. - Heart block: enhances atrioventricular conduction to maintain adequate cardiac output. - Asthma (off‑label): provides bronchodilation when conventional therapies are insufficient.

Isoprenaline may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Tachycardia: rapid heart rate. - Palpitations: awareness of heartbeat. - Tremor: involuntary shaking. - Headache: mild to moderate pain. - Anxiety: nervousness or restlessness. - Nausea: upset stomach.

Serious or Rare Side Effects: - Arrhythmias: abnormal heart rhythms. - Myocardial ischemia: reduced blood flow to heart muscle. - Severe hypotension: dangerously low blood pressure. - Bronchospasm: paradoxical airway constriction. - Anaphylaxis: severe allergic reaction. - Cardiac arrest: sudden loss of heart function.

Careful monitoring and patient assessment are essential when using Isoprenaline.

- Cardiovascular monitoring: observe heart rate and rhythm continuously. - Dose titration: adjust infusion rate based on clinical response. - Contraindications: avoid in patients with uncontrolled tachyarrhythmias. - Caution in ischemic heart disease: monitor for chest pain. - Pregnancy and lactation: use only if benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from light and moisture.

Isoprenaline can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Beta‑blockers: antagonize therapeutic effect, may precipitate severe bradycardia. - MAO inhibitors: increase risk of hypertensive crisis. - Other sympathomimetics: additive cardiovascular stimulation.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may enhance negative inotropic effects. - Digoxin: risk of arrhythmias. - Diuretics: potential electrolyte disturbances affecting cardiac response. - Anesthetic agents: may potentiate hemodynamic instability.